05 March 2024
05 March 2024
The acceleration of the Phase III del-desiran programme comes months after a $2.3bn collaboration with Bristol Myers Squibb.
No new safety concerns linked to Zolgensma were identified during the trial.
CYP-001 is an off-the-shelf, iPSC-derived mesenchymal stem cell product candidate for intravenous infusion.
The company expects to report top-line data from the Spectra trial before the end of this year.
A new study suggests that Japanese patients with chronic conditions score lower than other developed countries across a range of metrics.
The ultra long-acting cabotegravir demonstrated the potential for dosing every four months to improve HIV treatment and prevention.
For Rare Disease Day, several panels organised by the FDA discussed the importance overcoming accessibility barriers during drug development.
The EMA has validated the jointly developed TROP2-directed therapy for patients with breast or lung cancer following positive Phase III data.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
